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Abstract
Background: Various signals are known to participate in the pathogenesis of lung fibrosis. Our aim was to
determine which signal is predominantly mobilized in the early inflammatory phase and thereafter modulates the
development of lung fibrosis.
Methods: Mice received a single dose of 3 mg/kg body weight of bleomycin (BLM) and were sacrificed at
designated days post-instillation (dpi). Lung homogenates and sections from mice in the early inflammatory phase
were subjected to phospho-protein array analysis and immunofluorescence studies, respectively. Bronchoalveolar
lavage fluid (BALF) from mice was subjected to an enzyme-linked immunosorbent assay (EIA) for interleukin (IL)-6
and evaluation of infiltrated cell populations. The effects of endogenous and exogenous IL-6 on the BLM-induced
apoptotic signal in A549 cells and type 2 pneumocytes were elucidated. In addition, the effect of IL-6-neutralizing
antibody on BLM-induced lung injury was evaluated.
Results: Phospho-protein array revealed that BLM induced phosphorylation of molecules downstream of the IL-6
receptor such as Stat3 and Akt in the lung at 3 dpi. At 3 dpi, immunofluorescence studies showed that signals of
phospho-Stat3 and -Akt were localized in type 2 pneumocytes, and that BLM-induced IL-6-like immunoreactivity
was predominantly observed in type 2 pneumocytes. Activation of caspases in BLM-treated A549 cells and type 2
pneumocytes was augmented by application of IL-6-neutralizing antibody, a PI3K inhibitor or a Stat3 inhibitor. EIA
revealed that BLM-induced IL-6 in BALF was biphasic, with the first increase from 0.5 to 3 dpi followed by the
second increase from 8 to 10 dpi. Blockade of the first increase of IL-6 by IL-6-neutralizing antibody enhanced
apoptosis of type 2 pneumocytes and neutrophilic infiltration and markedly accelerated fibrosis in the lung. In
contrast, blockade of the second increase of IL-6 by IL-6-neutralizing antibody ameliorated lung fibrosis.
Conclusions: The present study demonstrated that IL-6 could play a bidirectional role in the pathogenesis of lung
fibrosis. In particular, upregulation of IL-6 at the early inflammatory stage of BLM-injured lung has antifibrotic activity
through regulating the cell fate of type 2 pneumocytes in an autocrine/paracrine manner.
Background
Idiopathic pulmonary fibrosis (IPF) is a chronic, progres-
sive disease with an extremely poor prognosis [1]. Like-
wise, epidemiological studies have demonstrated that the
incidence and prevalence of IPF have been increasing in
most western societies in recent years [2]. Although there
are many ongoing clinical trials of radical treatment for
IPF, there is no effective pharmacological therapy to
improve the survival of patients with IPF [3].
BLM-induced pulmonary fibrosis in mice is the most
common experimental model of human IPF [4]. Genetically
modified mice subjected to bleomycin (BLM) instillation
provide a useful target molecule for therapeutic interven-
tion in IPF [5–8]. In these mice, fibrosis is closely linked to
an inflammatory response in the lung. On the other hand,
comprehensive gene expression analysis of BLM-induced
fibrotic lung has revealed that two distinct groups of genes
are involved in the inflammatory and fibrotic responses [9].
A reciprocal relationship between lung inflammation and
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fibrosis has also been reported [10]. Furthermore, most pa-
tients who present to clinicians with subjective symptoms
show a reduction of forced vital capacity (FVC), indicating
that fibrosis is already present [11]. Hence, whether
experimental evidence-based anti-inflammatory therapy is
effective against lung fibrosis remains under debate [12].
Recently, the concept that IPF results from alveolar
epithelial cell injury with scant inflammation has been
generally accepted [13]. Many different molecular
processes such as epithelial mesenchymal transition
[14], apoptosis [15], endoplasmic reticulum stress [16],
telomere shortening-associated senescence [17], and hyper-
secretion of MUC5B caused by a point mutation in the
promoter region of the gene [18] are involved in the mech-
anisms of epithelial injury-based fibrosis. BLM administra-
tion can recapitulate epithelial injury-induced lung fibrosis
in mice [4]. Thus, to address the complex mechanisms of
the pathophysiological events in the development of lung fi-
brosis, BLM is a useful tool.
IL-6 is a pleiotropic cytokine and functions as a proin-
flammatory factor as well as a profibrotic factor in BLM-
induced lung fibrosis [19]. Recently, besides TGF-β/Smad3
signaling, the signaling loop of IL-6/gp130/Stat3 has been
shown to play a crucial role in the pathogenesis of lung
fibrosis [20]. Furthermore, blockade of the IL-6 signal
during the chronic stages of lung injury shows a beneficial
effect on lung fibrosis [21, 22]. In contrast, BLM-induced
IL-6 has a cytoprotective effect on alveolar epithelial cells
under stress with reactive oxygen species (ROS) [23]. Like-
wise, the IL-6/Stat3/Akt signaling axis plays a protective
role in type 2 pneumocytes by regulating surfactant homeo-
stasis [24]. These findings suggest the possibility that IL-6
also plays a protective role in epithelial injury-based fibrosis.
However, this possibility has not been shown in vivo.
Here, we first elucidated which intracellular signal was
predominantly activated at the early inflammatory stage of
BLM-injured lung by a phospho-protein array and focused
on the pathophysiological role of IL-6. Then, we demon-
strated in vivo and in vitro that endogenous IL-6 shows a
counter-effect on BLM-induced apoptosis of type 2 pneu-
mocytes in an autocrine/paracrine manner through activa-
tion of the Stat3/Akt signaling axis. In the bronchoalveolar
space, induction of IL-6 by BLM was characterized by a
biphasic response. Neutralization of IL-6 at the early
fibrotic stage of BLM-induced lung injury significantly
ameliorated lung fibrosis. However, it is noteworthy that
neutralization of IL-6 at the early inflammatory stage of




Male C57BL/6 mice at 10 weeks of age were purchased
from Clea Japan (Tokyo, Japan). Animals were housed in
the Animal Resource Facility of Chiba University under
pathogen-free conditions and cared for according to the
animal care guidelines of Chiba University. The studies
were performed according to an animal protocol approved
by the Animal Welfare Committee of Chiba University.
BLM-induced lung injury model
Mice under anesthesia with isoflurane inhalation were
given a single intratracheal injection of BLM hydrochlor-
ide (3 mg/kg; Nippon Kayaku, Tokyo, Japan) dissolved in
phosphate-buffered saline (PBS), using a Microsprayer®
atomizer (PennCentury, Philadelphia, PA). Control mice
received sham treatment with PBS.
Phospho-protein array
At 3 days post-instillation (dpi), mice under anesthesia were
intracardially perfused with ice-cold PBS to thoroughly
wash out blood cells in the lungs and sacrificed. Lung lobes
separated from the trachea and the main bronchi were
homogenized in ice-cold lysis buffer [25] and centrifuged at
9000 × g for 15 min at 4 °C. The resulting supernatant
(400 μg protein) was analyzed using a Pathscan Antibody
Array kit (Cell Signaling Technology, Danvers, MA).
Detection of phosphorylation of 39 proteins in the lung
sample was performed according to the manufacturer’s
protocol. Using a densitometer, each signal was normalized
to the positive internal control included in the array
membrane and expressed in arbitrary units.
Immunofluorescence study
Mice were sacrificed at 3 or 8 dpi, and the lung lobes were
fixed, dehydrated and frozen. Freshly cut lung sections
(5 μm thickness) placed on poly-L-lysine-coated slides were
pretreated with 1:10 FcR blocking agent (Miltenyi Biotech,
Gladbach, Germany) for 10 min and reacted with various
antibodies as follows: goat anti-prosurfactant protein
(proSP)-C antibody (Santa Cruz Biotech., Santa Cruz, CA),
rabbit anti-phospho-Stat3 (Cell Signaling Technology),
rabbit anti-phospho-Akt antibody (Cell Signaling Technol-
ogy), rabbit anti-Iba 1 antibody (WAKO, Osaka, Japan), rat
anti-mouse IL-6 antibody (Biolegend, San Diego, CA),
rabbit anti-S100A4 antibody (Abcam, Cambridge, UK) or
mouse anti-smooth muscle α-actin/SMA (Sigma-Aldrich,
St. Louis, MO). After staining with each appropriate
fluorescein-conjugated second antibody, the sections were
observed under a fluorescence microscope (Axio Imager
A2, Zeiss, Oberkochen, Germany). Nuclei were stained with
4’6’-diamino-2-phenylindole (DAPI).
Effect of IL-6 signal on BLM-induced apoptosis in A549
cells and primary cultured alveolar epithelial cells
A human lung adenocarcinoma epithelial cell line, A549,
was purchased from European Collection of Cell Cultures
(Salisbury, UK). Primary cultured alveolar epithelial cells
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were prepared from mice according to a method previ-
ously described with modifications [26]. The primary
cultured cells were characterized by immunofluorescence
study with rabbit anti-proSP-C antibody [27] and hamster
anti-podoplanin/gp36 antibody (Abcam) in combination
with Alexa Fluor 488-chicken anti-rabbit IgG and Alexa
Fluor 594-goat anti-hamster IgG (Life Technologies,
Carlsbad, CA). Then, SP-C+gp36− cells (purity > 90 %)
were used as alveolar epithelial cells for the following
experiments.
After 24 h of serum deprivation in Dulbecco's Modified
Eagle's Medium (DMEM) (WAKO) containing 0.2 % fatty
acid-free BSA (Sigma-Aldrich), A549 cells and primary
cultured alveolar epithelial cells on 24-well plates were
stimulated with BLM (100 μg/ml) for 12 h. The cell lysates
from A549 and primary cultured alveolar epithelial cells
were subjected to western blot (WB) with anti-human
cleaved caspase-8 (Asp391) antibody (Cell Signaling Tech-
nology) and anti-cleaved caspase-3 (Asp175) antibody (Cell
Signaling Technology), respectively. To investigate the
effects of human IL-6 (3 and 10 ng/ml, Peprotech, Rocky
Hill, NJ), human IL-6-neutralizing antibody (2 μg/ml, clone
MQ2-13A5, Biolegend), mouse IL-6-neutralizing antibody
(2 μg/ml, clone MP5-20 F3, Biolegend), rat IgG1κ isotype
control for IL-6-neutralizing antibodies (2 μg/ml, Biole-
gend), LY294002 (a PI3K inhibitor, 1 μM, Cell Signaling
Technology) and S3I-201 (a Stat3 inhibitor, 1 μM, Sigma-
Aldrich), each agent was added to the culture medium
30 min prior to BLM stimulation.
Effect of IL-6 signal on BLM-induced cytokine expression
in primary cultured alveolar epithelial cells
Primary cultured alveolar epithelial cells on 12-well plates
were stimulated with BLM (100 μg/ml) for 12 h in the
presence of mouse IL-6-neutralizing antibody (2 μg/ml) or
isotype control. Then, supernatants were collected and
centrifuged at 400 × g for 15 min at 4 °C. The resulting
supernatants were subjected to Mouse Cytokine Antibody
Array C1 (RayBiotech, Inc., Norcross, GA) and changes in
expression levels of 22 inflammation-related proteins in
the supernatant sample were evaluated. The array was
performed according to the manufacturer’s instructions.
Measurement of IL-6 level in bronchoalveolar lavage fluid
Mice with instillation of BLM were anesthetized and sacri-
ficed on days 0, 0.5, 1, 2, 3, 5, 7, 8, 9, 10 and 11. Then, the
lungs of each mouse were lavaged with 1 ml ice-cold PBS
twice via the exposed trachea cannulated with a 20-gauge
catheter. Collected bronchoalveolar lavage fluid (BALF) was
centrifuged at 400 x g for 10 min. The resulting supernatant
was subjected to IL-6 measurement using a mouse IL-6
ELISA MAX™ Standard (Biolegend), according to the man-
ufacturer’s protocol.
Effects of IL-6-neutralizing antibody on BLM-induced lung
injury
Mouse IL-6-neutralizing antibody was intratracheally
injected in BLM-instilled mice using a Microsprayer®
atomizer. IL-6-neutralizing antibody was administered at
15 μg/body, and isotype control at 15 μg/body, for each
injection.
For neutralization of IL-6 at the early inflammatory stage
of BLM-induced lung injury, IL-6-neutralizing antibody
was administered at 6, 30 and 54 h (0, 1 and 2 dpi) after
instillation of BLM. Control mice received treatment with
isotype control. Then, examination of apoptosis of type 2
pneumocytes, analysis of cell populations in BALF and
histopathological study were performed. For examination
of apoptosis, mice were anesthetized, sacrificed and intra-
cardially perfused with PBS at 3 dpi, and the lungs were
lavaged twice with 1 ml PBS via the exposed trachea cannu-
lated with a 20-gauge catheter. Then, 1 ml PBS containing
YO-PRO-1 (1:100, Life Technologies, Carlsbad, CA) and
propidium iodide (0.5 μM, Life Technologies) was injected
into the bronchoalveolar space through the catheter. After
15 min, the lungs were lavaged four times with 1 ml ice-
cold PBS, and the bronchoalveolar space was filled with
4 % PFA. The lungs were dissected out, further fixed, frozen
and sectioned. The population of apoptotic and necrotic
cells was examined under a fluorescence microscope, and
type 2 pneumocytes were confirmed by observing the
phase-contrast of the same visual field. Then, the apoptotic
or necrotic signal, corresponding to type 2 pneumocytes,
was estimated. For evaluation of infiltrated cells, mice
under anesthesia were sacrificed at 7 dpi, and the lungs of
each mouse were lavaged with 1 ml ice-cold PBS twice via
the exposed trachea cannulated with a 20-gauge catheter.
After centrifugation of BALF, collected total cell count was
measured using a hemocytometer. The differential cell
count was determined by manually counting 200 cells/
mouse after staining with Diff-Quick (Sysmex Co., Kobe,
Japan). For histopathological studies, mice under anesthesia
were sacrificed at 7 and 14 dpi. The lungs were perfused,
dissected out, fixed, sectioned and stained with Masson’s
trichrome to visualize fibrotic lesions. Semi-quantitative
elucidation of lung fibrotic changes was performed accord-
ing to the previously described method with a slight modifi-
cation [28]. In brief, longitudinal sections along the central
axis of the right lung (apical, azygous and diaphragmatic
lobes) and the left lung were prepared, and one section
from each lung was randomly selected (2 sections/mouse).
Under 200x magnification, 10 fields in each section were
randomly chosen, scored, and the average score was
calculated.
For neutralization of IL-6 at the early fibrotic stage of
BLM-induced lung injury, IL-6-neutralizing antibody
was administered at 8, 9 and 10 days after instillation of
BLM. Control mice received treatment with isotype
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control. Then, changes in body weight and survival rate
were monitored until 14 dpi. At 14 dpi, mice were
sacrificed under anesthesia, and the fibrotic changes in
lung sections were visualized with Masson’s trichrome
staining and scored according to the method described
above.
Statistical analysis
Data are expressed as mean ± S.E.M. Statistical analysis was
conducted using Graphpad Prism Version 6 (GraphPad
Software Inc., San Diego, CA). Statistical significance was
determined by Student’s t test or analysis of variance
(ANOVA) followed by the Tukey's test, and p values < 0.05
were considered significant.
Results
Activation of IL-6 signal in type 2 pneumocytes at early
inflammatory stage of BLM-induced lung injury
It is well known that BLM-induced lung injury is composed
of two phases, an inflammatory phase characterized by
Fig. 1 Effect of BLM on phosphorylation of signaling proteins in lung. Lysates (400 μg) from the lungs of mice instilled with PBS or BLM (3 dpi)
were subjected to Pathscan Antibody Array. a Typical profile of BLM-induced protein phosphorylation. Proteins with increased phosphorylation
levels in response to BLM are boxed. In particular, phospho-Akt and -Stat3 are boxed by a double-line. b Phosphorylation levels of these proteins
in the lungs of mice instilled with PBS (white bars) and BLM (black bars). Using a densitometer, each signal was normalized to the positive internal
controls included in the array glass and expressed in arbitrary units. Average signal of the positive internal controls is expressed as 10 arbitrary
units. Data are shown as mean ± S.E.M. of three independent experiments. The difference between the two groups (PBS and BLM) was statistically
significant (*P < 0.05) by Student’s t-test for unpaired values
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recruitment of leukocytes within one week and a fibrotic
phase characterized by fibroblast proliferation and synthesis
of extracellular matrix during the second week [29]. To
elucidate which intracellular signal is predominantly acti-
vated at the early inflammatory stage of the BLM-injured
lung, a phospho-protein array was performed. At 3 dpi,
phosphorylation of several proteins such as Akt, Erk1/2,
HER3, IGR-IR, S6 ribosomal protein, Src and Stat3 was
induced in lung treated with BLM compared with lung
treated with PBS (Fig. 1a). Phosphorylation level of each
protein analyzed by a densitometer is shown in Fig. 1b.
Among these proteins, we focused on Akt and Stat3 as
prerequisite signaling molecules located downstream of
the IL-6 receptor [30], since, in particular, little is still
known about sites where IL-6 predominantly acts in early
phase of BLM-induced lung injury. We examined the
localization of activated forms of Akt and Stat3, and
identified the cells expressing IL-6 at the early inflamma-
tory stage of BLM-induced lung injury.
As shown in Fig. 2a, phosphorylated Akt and Stat3 were
mostly observed in SP-C+ cells in response to BLM at 3
dpi. Phospho-Akt-like immunoreactivity (LI) was detected
in the cell body including the plasma membrane of SP-C+
cells. On the other hand, phospho-Stat3-LI overlapped with
nuclei identified by DAPI. These phenomena are accordant
with the facts that activated Akt is recruited to the plasma
membrane, and that activated Stat3 forms a dimer and is
then translocated to the nucleus [30, 31], indicating that
the IL-6 signal is activated in type 2 pneumocytes at the
early inflammatory stage of BLM-induced lung injury. At 3
dpi, when activation of Stat3 and Akt was observed in type
2 pneumocytes, IL-6-LI was mostly detected in SP-C+ cells
Fig. 2 Localization of phospho-Akt and -Stat3 and expression of IL-6 at early inflammatory stage of BLM-injured lung. a Lung sections of mice
instilled with PBS or BLM (3 dpi) were stained with anti-phospho-Akt or anti-phospho-Stat3 antibody in combination with anti-proSP-C antibody
followed by reaction with Alexa 488- or Alexa 594-conjugated second antibodies (488 for phospho-Akt and -Stat3; 594 for SP-C). Arrowheads
indicate phospho-Akt+SP-C+ and phospho-Stat3+SP-C+ cells. b Lung sections from mice instilled with BLM (3 dpi) were stained with anti-IL-6
antibody in combination with anti-proSP-C or anti-Iba1 antibody followed by reaction with Alexa 488- or Alexa 594-conjugated second antibodies
(488 for IL-6; 594 for SP-C and Iba1). Arrowheads indicate IL-6+SP-C+ and IL-6+Iba1+ cells. Asterisk indicates a cell with macrophage-like
morphological features. c Lung sections from mice instilled with BLM (3 dpi) were stained with anti-IL-6, anti-proSP-C and anti-Iba1 antibodies
followed by reaction with Alexa 350-, 488- and Alexa 594-conjugated second antibodies. Data are shown as mean ± S.E.M. (n = 6). Nuclei were
stained with DAPI. Similar results to the immunofluorescence profiles in (a) and (b) were observed in four independent experiments
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(Fig. 2b). Besides type 2 pneumocytes, large cells showing
macrophage-like morphological features in the alveolar
space exhibited IL-6-LI (Fig. 2b inset). Then, whether Iba1+
macrophages could be positive for IL-6 was investigated.
As shown in Fig. 2b, Iba1+IL-6+ cells were sparsely
observed in lung sections, indicating that the main source
of IL-6 could be type 2 pneumocytes but not macrophages
at the early inflammatory stage of BLM-induced lung
injury. By triple staining of lung sections from mice at 3 dpi
with anti-IL-6, anti-proSP-C and anti-Iba1 antibodies,
approximately 70 % and 14 % of IL-6+ cells were positive
for SP-C and Iba1, respectively (Fig. 2c). We have
confirmed that IL-6-LI was not observed in lung treated
with PBS (data not shown). Then, we hypothesized that IL-
6 induced by BLM could affect the cell fate and induce
functional change of type 2 pneumocytes in an autocrine/
paracrine manner and assessed this hypothesis in vitro.
IL-6 has counter effect on BLM-induced cell death of type
2 pneumocytes in vitro
Using A549 cells, which are widely used as an in vitro
model for type II pulmonary epithelial cells, we first
investigated the effects of endogenous and exogenous
IL-6 on BLM-induced activation of caspase 8, an apop-
totic signal [32]. As shown in Fig. 3a, BLM increased
the production of cleaved caspase 8, the activated form
of caspase 8. Blockade of endogenous IL-6 by anti-IL-6
antibody augmented BLM-induced production of
cleaved caspase 8. Accordingly, treatment of the cells
with a PI3K inhibitor, LY294002, or a Stat3 inhibitor,
S3I-201, augmented BLM-induced production of
cleaved caspase 8, indicating that inhibition of the IL-6
signal induces an apoptotic signal in A549 cells. In
contrast, application of IL-6 to the cells suppressed
BLM-induced production of cleaved caspase 8 in a
dose-dependent manner (Fig. 3b). Also in primary
cultured type 2 pneumocytes, treatment of the cells
with an IL-6-neutralizing antibody, LY294002 or S3I-
201, augmented BLM-induced production of cleaved
caspase 3, another apoptotic signal [32] (Fig. 3c). We
have confirmed that application of IL-6 to both A549
cells and primary cultured type 2 pneumocytes induces
phosphorylation of Akt and Stat3 in the cells (data not
shown). Hence, endogenous IL-6 plays a cytoprotective
role in type 2 pneumocytes through activation of Akt
and Stat3 in an autocrine/paracrine manner. Then, we
investigated whether endogenous IL-6 also affects cellu-
lar function of type 2 pneumocytes.
Endogenous IL-6 modulates BLM-induced cytokine
production by type 2 pneumocytes
It is well known that type 2 pneumocytes are involved in
the intra-alveolar cytokine network [33]. Thus, we inves-
tigated whether application of IL-6-neutralizing antibody
affects BLM-induced cytokine release from primary
cultured type 2 pneumocytes. As shown in Fig. 4a, BLM
induced the production of various cytokines/chemokines
such as granulocyte macrophage colony-stimulating factor
(GM-CSF), IL-2, IL-4, IL-6, IL-9, IL-12/p70, IL-13, mono-
cyte chemoattractant protein (MCP)-1, MCP-5, regulated
on activation, normal T cell expressed and secreted
(RANTES), soluble tumor necrosis factor receptor (sTNFR)
I and thrombopoietin (THPO). Among the BLM-induced
proteins, densitometric analysis revealed that several
molecules were significantly sensitive to blockade of
endogenous IL-6. Blockade of endogenous IL-6
enhanced the BLM-induced production of GM-CSF,
IL-2 and IL-13 but suppressed the BLM-induced
Fig. 3 Endogenous IL-6 suppresses BLM-induced apoptotic signal in
alveolar epithelial cells. a Effect of human IL-6-neutralizing antibody, a
PI3K inhibitor LY294002, and a Stat3 inhibitor S3I-201 on BLM-induced
caspase 8 activation in A549 cells. Lysates (20 μg) from cells treated
with or without BLM were subjected to WB analysis for detection of
cleaved caspase 8. Application of human IL-6-neutralizing antibody,
control IgG, LY294002 and S3I-201 to the cells was performed 30 min
prior to BLM treatment. The same lysates were subjected to WB
analysis to determine the amount of β-actin as an internal control.
b Exogenous IL-6 inhibited BLM-induced caspase 8 activation in
A549 cells in a dose-dependent manner. The amount of β-actin of
each lane was determined as an internal control. c Effect of mouse
IL-6-neutralizing antibody, LY294002, and S3I-201 on BLM-induced
caspase 3 activation in primary cultured SP-C+ cells. The basic procedure
was the same as that for (a)
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production of IL-9, MCP-1 and THPO in type 2 pneu-
mocytes (Fig. 4b).
Time-dependent induction of IL-6 in BLM-instilled lung
To elucidate how the IL-6-mediated events affect
BLM-induced lung injury, the relationships between IL-
6 neutralization and the pathogenesis of BLM-injured
lung were evaluated. Before applying anti-IL-6 antibody
to mice, the time-dependent increase of IL-6 level in
BALF was observed to plan the schedule of IL-6
neutralization. As shown in Fig. 5, BLM induced a
biphasic increase in IL-6 in BALF. The first peak was
observed at 0.5 dpi, followed by a plateau from 1 to 3
dpi and a decline to the control level at 5 dpi; i.e.,
induction of IL-6 at the early inflammatory stage. The
second peak was observed at 8 dpi and gradually
declined to the control level at 11 dpi; i.e., induction of
IL-6 at the early fibrotic stage.
Blockade of IL-6 at early inflammatory stage of BLM-
induced lung injury accelerates lung fibrosis
To block the first peak of IL-6, IL-6-neutralizing anti-
body was administered to mice at 6, 30 and 54 h (0, 1
Fig. 4 Endogenous IL-6 modulates BLM-sensitive cytokine production in type 2 pneumocytes. a Typical expression profile of cytokines. Primary
cultured type 2 pneumocytes from mice were treated with BLM in the presence or absence of mouse IL-6-neutralizing antibody, and the
supernatants were subjected to Mouse Cytokine Antibody Array C1. Application of mouse IL-6-neutralizing antibody and control IgG to the cells
was performed 30 min prior to PBS or BLM treatment. The 12 molecules induced by BLM (BLM + control IgG) are numbered and indicated with
the correct location in the membrane map, compared with the unstimulated control (PBS + control IgG). Among the 12 proteins, IL-6-neutralizing
antibody (BLM+ anti-IL-6)-induced and -reduced molecules are indicated by squares with a double-line and a single-line, respectively. IL-6-neutralizing
antibody-insensitive molecules are indicated by a broken-line. We confirmed that the array profile of unstimulated control (PBS + control IgG) showed
no difference from that of PBS alone. b Changes in expression of IL-6-neutralizing antibody-sensitive molecules observed in WB array analyzed by
densitometer. Using a densitometer, each signal was normalized to the positive internal controls included in the array membrane and expressed in
arbitrary units. Average signal of the positive internal controls is expressed as 100 arbitrary units. Data are shown as mean ± S.E.M. of three independent
experiments. *P < 0.05, significantly different from value of BLM + control IgG group (ANOVA followed by Tukey's test)
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and 2 dpi) after instillation of BLM. As shown in Fig. 6a,
YO-PRO-1-permeable apoptotic type 2 pneumocytes
increased in response to BLM at 3 dpi. BLM-induced
apoptosis of the cells was significantly enhanced by
treatment of the lung with IL-6-neutralizing antibody
but not isotype control. On the other hand, necrotic
type 2 pneumocytes stained with the intercalating
agent, propidium iodide, were rarely observed, at least
under our experimental conditions (data not shown). In
addition, analysis of BALF revealed that infiltration of
neutrophils and lymphocytes increased in response to
BLM at 7 dpi. The BLM-induced neutrophilic infiltra-
tion was markedly enhanced by treatment of the lung
with IL-6-neutralizing antibody but not isotype control
(Fig. 6b).
Histopathological findings with Masson’s trichrome
staining revealed that weakly positive fibrotic lesions
were sparsely observed in sections of BLM-instilled
lung at 7 dpi. Treatment of BLM-instilled lung with
IL-6-neutralizing antibody but not isotype control
caused obvious fibrosis even at 7 dpi (Fig. 7a). This
finding was supported by analysis of the modified
Aschcroft scale. Compared with the PBS-instilled
group, BLM modestly but significantly increased the
Aschcroft score at 7 dpi, which was further increased
by application of IL-6-neutralizing antibody (Fig. 7b).
At 14 dpi, on the other hand, BLM induced obvious
lung fibrosis, with a similar grade to that of lung
treated with IL-6-neutralizing antibody or isotype con-
trol (Fig. 7a&b). In accord with those findings, the
changes in SMA expression revealed that application of
IL-6-neutralizing antibody markedly enhanced BLM-
induced fibrogenesis especially at 7dpi (Additional file
1: Figure S1).
Blockade of IL-6 at early fibrotic stage of BLM-induced
lung injury ameliorates lung fibrosis
To block the second peak of IL-6, IL-6-neutralizing anti-
body was administered to mice at 8, 9 and 10 dpi. As
shown in Fig. 8a, BLM-induced body weight loss of mice
was blocked by treatment with IL-6-neutralizing antibody.
Likewise, application of IL-6-neutralizing antibody im-
proved the survival rate (Fig. 8b). In accord with those
findings, BLM-induced lung fibrosis at 14 dpi was mark-
edly alleviated by application of IL-6-neutralizing anti-
body, which was supported by evaluation of the Ashcroft
score (Fig. 8c&d). To elucidate IL-6-expressing cells and
IL-6-acting sites at the early fibrotic stage of BLM-
induced lung injury, the localization of IL-6-LI and
phospho-Stat3-LI in lung sections at 8 dpi was investi-
gated. As shown in Fig. 9b, IL-6-LI was rarely observed in
SP-C+ type 2 pneumocytes. In contrast, Iba1+ cells were
frequently positive for IL-6, indicating that macrophages
could efficiently express IL-6 (Fig. 9c). At 8 dpi, fibrotic
lesions were observed in patches in lung sections stained
with Masson’s trichrome (Fig. 9a). In the fibrotic areas
where DAPI+ nuclei were condensed, S100A4+ foci occa-
sionally exhibited IL-6-LI, indicating that fibroblasts could
also express IL-6 (Fig. 9d). Although SP-C+phospho-
Stat3+ cells were hardly observed, phospho-Stat3-LI was
mostly localized in fibrotic areas where SMA+ myofibro-
blasts were extensively observed (Fig. 9e&f ).
Fig. 5 Time course of BLM-induced IL-6 level in BALF. BALF from
mice treated with BLM were subjected to ELISA for mouse IL-6 at
the indicated dpi. IL-6 level in BALF prepared from mice with PBS
treatment is shown as negative control (PBS). Data are shown as
mean ± S.E.M. (n = 4). *P < 0.05, significantly different from the PBS
value (ANOVA followed by Tukey's test)
Fig. 6 Blockade of IL-6 at early inflammatory stage of BLM-injured
lung enhances apotosis of type 2 pneumocytes and alveolitis. Mice
were divided into four groups: PBS group, BLM group, BLM + control
IgG group, and BLM + anti-IL-6 group. a Apoptotic type 2
pneumocytes were elucidated by counting YO-PRO-1-permeable
cells at 3 dpi. Data are shown as mean ± S.E.M. of twenty sections
from each individual (n = 5). *P < 0.05, significantly different from
value of BLM-treated lung (ANOVA followed by Tukey's test). b Effect
of IL-6-neutralizing antibody on change in number of infiltrated cells
into the lung. Data are shown as mean ± S.E.M. (n = 5). *P < 0.05,
significantly different from value of BLM-treated lung (ANOVA
followed by Tukey's test)
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Discussion
Comprehensive profiling of mRNA and protein expression
using microarray and WB array technology is useful for
evaluating the complex mechanisms of pathophysiological
events and to define a novel therapeutic target in a certain
disease [5, 9, 34, 35]. In addition to these analytical
options, WB array for phospho-proteins is a useful tool to
determine which intracellular signal is predominantly acti-
vated under a certain condition [36]. Based on the results
of phospho-protein array, we focused on Akt and Stat3,
downstream signaling molecules of the IL-6 receptor, for
the following reasons: 1) IL-6 induced in a variety of acute
and chronic inflammatory diseases plays a major role as a
trigger for acute-phase protein synthesis [37]. 2) In
pulmonary inflammatory diseases, bipotential functions of
IL-6 in inflammation were shown using IL-6−/− mice. IL-6
can mediate persistent inflammation and subsequent
fibrotic changes in the lung [19]. On the other hand, IL-6
contributes to host defense against pneumococcal pneu-
monia through downregulating activation of the cytokine
network in the lung [38]. 3) During the fibrotic stage of
BLM-induced lung injury, the IL-6/Stat3 signaling axis
promotes lung fibrosis [21, 22]. However, radical oxygen
species (ROS) mimicking cytotoxicity of BLM induce
apoptosis of several types of cells including type II alveolar
epithelial cells in organotypic lung slices, which was
marked in IL-6−/− slices and wild-type (WT) slices treated
with IL-6-neutralizing antibody compared with the case of
WT slices treated with isotype control [23]. This finding
tempts us to consider that IL-6 may also play an antifibrotic
role in epithelial injury-based fibrosis. Hence, temporal and
spatial differences in IL-6-acting site might affect the patho-
physiological outcome in the BLM-injured lung. Indeed,
the concept that the role of IL-6 signaling may differ
between acute and chronic stages of lung disease is sug-
gested [21]. However, whether IL-6 modulates epithelial
injury-based fibrosis in the BLM-instilled mouse model has
still not been clarified.
At the early inflammatory stage of BLM-induced lung
injury, immunofluorescence studies revealed the predom-
inantly IL-6-acting site and IL-6-producing cell. The phos-
phorylated forms of Akt and Stat3 were mostly restricted
to type 2 pneumocytes, indicating that type 2 pneumo-
cytes respond as the predominantly IL-6-acting site. The
phosphorylated form of Stat3 was detected in SP-C+ cells
even in the PBS-treated lung, which is similar to the result
of phospho-protein array showing a clear signal of
phospho-Stat3 in the homogenate of PBS-treated lung,
Fig. 7 Blockade of IL-6 at early inflammatory stage of BLM-injured lung accelerates lung fibrosis. Mice were divided into four groups: PBS group,
BLM group, BLM + control IgG group, and BLM + anti-IL-6 group. a Effect of IL-6-neutralizing antibody on BLM-induced histopathological changes
in the lung. Lung sections from each group at 7 and 14 dpi were stained with Masson’s trichrome to visualize fibrotic lesions. b Semi-quantitative
measurement of lung fibrotic change. Eight mice in each group were used. Data are shown as scores of sixteen sections (two sections/mouse).
Bars represent median values. *P < 0.05, significantly different from value of BLM-treated lung (ANOVA followed by Tukey's test). The difference
between the two groups (7 and 14 dpi of BLM) was statistically significant (#) by Student’s t-test for unpaired values. n.s., no significant difference
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suggesting that intrinsic activity of Stat3 may be relatively
high in type 2 pneumocytes. On the other hand, type 2
pneumocytes also function as the predominant IL-6-
producing cells when activation of Stat3 and Akt was de-
tected in type 2 pneumocytes. Although macrophages
could also produce IL-6, their contribution was less than
that of type 2 pneumocytes. This finding is supported by a
previous report that IL-6 secretion from type 2 pneumo-
cytes is markedly higher than that from alveolar macro-
phages [39]. These results suggest the possibility that IL-6
induced by BLM affects the cell fate and function of type 2
pneumocytes in an autocrine/paracrine manner, at least in
the early inflammatory phase. Then, we examined this pos-
sibility using cultured cells.
In both A549 cells and primary cultured type 2 pneu-
mocytes, application of IL-6-neutralizing antibody, a PI3K
inhibitor or a Stat3 inhibitor augmented BLM-induced
production of cleaved caspases. These results clearly
suggest that BLM mobilizes an apoptotic signal in type 2
pneumocytes and simultaneously induces IL-6 production
as a compensatory mechanism. Likewise, the IL-6/PI3K/
Akt and IL-6/ Stat3 signaling axes can protect alveolar
epithelial cells from BLM-induced cell death. This notion is
supported by previous reports as follows: blockade of the
PI3K/Akt pathway potentiates apoptosis induced by a
cyclin-dependent kinase inhibitor in A549 cells [40]; kera-
tinocyte growth factor can inhibit Fas-mediated apoptosis
of A549 cells through activation of the PI3K/Akt pathway
[41]; Stat3 in type 2 pneumocytes possibly contributes to
alveolar epithelial cell survival and surfactant/lipid synthe-
sis, which are necessary for protection of the lung during
injury [42]; and the IL-6/Stat3/Akt signaling axis plays a
protective role in type 2 pneumocytes [24]. Hence, Akt
activated by IL-6 may play a cytoprotective role in concert
with Stat3 in type 2 pneumocytes of the lung instilled with
BLM. We have confirmed that activation of Akt and Stat3
is induced by BLM in alveolar type II cells within a few
hours, which is relatively faster than the time course of
BLM-induced IL-6 synthesis/release (data not shown). This
finding indicates that IL-6-independent and BLM-induced
PI3K/Akt and Stat3 activation also exist in alveolar type II
cells and can explain the finding that the apoptotic signal
augmented by a PI3K inhibitor or a Stat3 inhibitor was
stronger than that augmented by IL-6-neutralizing anti-
body. However, the effect of IL-6-neutralizing antibody
suggests that at least IL-6-dependent Akt and Stat3
Fig. 8 Blockade of IL-6 at early fibrotic stage of BLM-injured lung ameliorates lung fibrosis. Mice were divided into two groups: BLM + control IgG
group, and BLM + anti-IL-6 group. a Body weight (BW) of BLM-instilled mice with or without IL-6-neutralizing antibody treatment. Time-dependent
change in BW is expressed as percentage of BW of each mouse just before BLM instillation. *P < 0.05, significantly different from BLM+ control IgG
group at each indicated time point by Student’s t-test. Data represent mean ± S.E.M. (n = 6). b Survival rate of BLM-instilled mice with or without
IL-6-neutralizing antibody treatment. Data represent mean ± S.E.M. (n = 12). c Effect of IL-6-neutralizing antibody on BLM-induced histopathological
change in the lung. Lung sections from each group at 14 dpi were stained with Masson’s trichrome to visualize fibrotic lesions. d Semi-quantitative
measurement of lung fibrotic change. Six mice in each group were used. Data are shown as mean ± S.E.M. of twelve sections (two sections/mouse).
*P < 0.05, significantly different from BLM+ control IgG group by Student’s t-test
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activation can function as a survival signal in BLM-treated
type 2 pneumocytes in an autocrine/paracrine manner.
Moreover, application of IL-6-neutralizing antibody to type
2 pneumocytes also affected their cytokine-producing activ-
ity under stimulation with BLM. The BLM-induced
production of several cytokines such as GM-CSF, IL-2,
IL-9, IL-13, MCP-1 and THPO was modulated by en-
dogenous IL-6 in type 2 pneumocytes. GM-CSF and IL-
9 play a protective role against BLM-induced lung fi-
brosis through a prostaglandin-dependent mechanism
[43, 44]. In contrast, IL-13 and MCP-1 contribute to
the development of BLM-induced lung fibrosis [45, 46].
On the other hand, IL-2 is shown to be involved not in
fibrosis but in lymphocytic infiltration in the lung in-
stilled with BLM [47]. THPO has not been shown to be
related to lung injury, but plays a protective role in liver
fibrosis [48]. Hence, the stimulatory effect of IL-6 on
expression of antifibrotic cytokines, IL-9 and THPO,
and the inhibitory effect of IL-6 on expression of proin-
flammatory and profibrotic cytokines, IL-2 and IL-13,
may improve the microenvironment in the lung ex-
posed to BLM. In conjunction with the cytoprotective
activity of IL-6, at least IL-6 was upregulated predomin-
antly in type 2 pneumocytes at the early inflammatory
stage, and may exert counter effects on the develop-
ment of BLM-induced lung injury. In the BLM-instilled
lung, IL-6 was induced at both the early inflammatory
stage and early fibrotic stage. Then, we further investi-
gated how blockade of IL-6 at each stage affects the
pathophysiological outcome of BLM-induced lung
injury.
According to our expectation, blockade of IL-6 at the
early inflammatory stage of BLM-induced lung injury
enhanced apoptosis of type 2 pneumocytes. In addition, an
increase in population of neutrophils in BALF from BLM-
instilled mice was also enhanced by IL-6-neutralizing
antibody but not isotype control. Although a precise evalu-
ation of the inflammatory cell populations in the lung
parenchyma contributing to the severity of fibrosis is
needed [20], the increase in neutrophils in BALF suggests
that blockade of IL-6 at the early inflammatory stage of
BLM-induced lung injury at least enhances lung inflamma-
tion. Furthremore, even at the transitional period from the
inflammatory phase to the fibrotic phase, the application of
IL-6-neutralizing antibody to the lung instilled with BLM
resulted in obvious fibrosis. The exact reason why blockade
of IL-6 at the early inflammatory stage of BLM-induced
lung injury enhanced fibrotic formation at 7 dpi but not 14
dpi is unclear in the present study. At 14 dpi, alveoli nearly
obliterated with fibrous masses that are Grade 7 by
Ashcroft score were observed more frequently in BLM +
anti-IL-6 group than both BLM and BLM+ control IgG
groups. Hence, histopathological observation or biochem-
ical analysis more than 14 days may be needed. In the
normal alveoli of most patients with IPF, numerous type 2
pneumocytes actively undergo programmed cell death, sug-
gesting epithelial injury-based mechanisms of lung fibrosis
[49]. This concept has been clearly validated by the finding
Fig. 9 Localization of phospho-Stat3 and expression of IL-6 at early fibrotic stage of BLM-injured lung. Lung sections from mice instilled with BLM
(8 dpi) were used for the following experiments. a Masson’s trichrome staining. b Lung sections were stained with anti-IL-6 and anti-proSP-C
antibodies followed by reaction with Alexa 488- or Alexa 594-conjugated second antibodies (488 for IL-6; 594 for SP-C). Arrowhead indicates
IL-6+SP-C+ cell. c Lung sections were stained with anti-IL-6 and anti-Iba1 antibodies followed by reaction with Alexa 488- or Alexa 594-conjugated
second antibodies (488 for IL-6; 594 for Iba1). Arrowheads indicate IL-6+Iba1+ cells. d Lung sections were stained with anti-IL-6 and anti-S100A4 anti-
bodies followed by reaction with Alexa 488- or Alexa 594-conjugated second antibodies (488 for IL-6; 594 for S100A4). e Lung sections were
stained with anti-proSP-C and anti-phospho-Stat3 antibodies followed by reaction with Alexa 488- or Alexa 594-conjugated second antibodies
(488 for SP-C; 594 for phospho-Stat3). f Lung sections were stained with anti-SMA and anti-phospho-Stat3 antibodies followed by reaction with
Alexa 488- or Alexa 594-conjugated second antibodies (488 for SMA; 594 for phospho-Stat3). Nuclei were stained with DAPI. Similar results to
the histopathological changes and immunofluorescence profiles were observed in four independent experiments
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that induction of type 2 pneumocyte-specific cell death by a
genetically engineered method leads to pulmonary fibrosis
[15]. Taking these findings together, IL-6 at the early
inflammatory stage of BLM-induced lung injury functions
as an inhibitory factor in the epithelial injury-based mecha-
nisms of lung fibrosis. The question arose as to whether
blockade of the protective role of IL-6 could affect BLM-
induced TGF-β1 expression because a correlation between
IL-6 signal and TGF-β1 expression has been shown in
BLM-challenged mice [19]. It is well known that TGF-β/
smad3 signaling can stimulate fibroblast differentiation and
epithelial mesenchymal transition and that mouse with
Smad3-deficiency shows resistance to BLM-induced lung
fibrosis [50]. Moreover, a genetic inhibition of TGF-β/TβRII
signaling axis in alveolar type II cells limits BLM-induced
fibrogenesis by increasing fibroblast apoptosis [51]. Thus,
TGF-β1 is closely associated with epithelial cell fate and
subsequent fibrotic formation. Blockade of IL-6 at the early
inflammatory stage of BLM-induced lung injury signifi-
cantly enhanced BLM-induced TGF-β1 mRNA expression
at 7 dpi (Additional file 2: Figure S2). Although the precise
mechanism of this finding is still unclear, the upregulation
of BLM-induced TGF-β1 may partly contribute to obvious
fibrotic formation manifested by blocking IL-6 at the early
inflammatory stage of BLM-induced lung injury.
In contrast to the case of blocking the first peak of IL-6,
blockade of IL-6 at the early fibrotic stage of BLM-
induced lung injury improved both the body weight loss
and the survival rate of mice. Likewise, BLM-induced lung
fibrosis was significantly inhibited by IL-6-neutralizing
antibody at 14 dpi. The possibility that blockade of IL-6 at
the early fibrotic stage of BLM-induced lung injury simply
delayed the onset of BLM-induced fibrotic formation
remains. In a preliminary study, however, severe fibrosis
induced by BLM was not observed up to 40 dpi in mice
administered with IL-6-neutralizing antibody. These
results suggest that IL-6 positively contributes to lung
fibrosis under a fibrosis-establishing state. This finding
showed good agreement with previous reports that lung
fibrosis is ameliorated by genetic or pharmacologic block-
ade of IL-6 [19, 21]. In addition, the abundant localization
of phospho-Stat3 in fibrotic areas at the early fibrotic stage
of BLM-induced lung injury was in accord with previous
reports on lung sections from both mice with lung fibrosis
and patients with IPF [20, 22]. It has been clearly shown
that IL-6/gp130/Stat3 signaling axis in lung fibroblasts
derived from IPF patients enhances the resistance to
apoptosis by upregulating Bcl-2 expression [52]. Likewise,
viral delivery of oncostatin M, one of IL-6 family members
sharing gp130-signaling subunit, to the lung induced
severe fibrosis associated with Stat3 activation in a TGF-β/
smad3-independent manner [20, 53]. Hence, localization of
activated Stat3 in fibrotic area may be one of pathophysio-
logical indices in IL-6 family-mediated fibrogenesis. At the
early fibrotic stage of BLM-induced lung injury, the IL-6-
producing cells were mainly macrophages and fibroblasts
but not type 2 pneumocytes, and phospho-Stat3 was not
observed in type 2 pneumocyte. Thus, an autocrine/para-
crine loop of IL-6 signaling was not observed in type 2
pneumocytes. The changes in IL-6-producing and -acting
cells between different injury stages may at least support a
bidirectional role of IL-6 in BLM-induced lung fibrosis.
Targeting IL-6 is a rational approach to various auto-
immune and chronic inflammatory diseases [54]. Likewise,
the IL-6/gp130/Stat3 signaling axis is expected to be a
new therapeutic target in IPF [20, 22]. Furthermore,
neutralization of IL-6, especially at the fibrotic stage of
lung injury, significantly inhibits the progression of lung
fibrosis [21]. Thus, an anti-IL-6 strategy may be beneficial
for IPF patients. However, recent clinical case reports
presented patients with established rheumatoid arthritis
(RA) with RA-associated interstitial lung disease (ILD)
treated with tocilizumab, an anti-IL-6 receptor monoclo-
nal antibody, who had an acute exacerbation of interstitial
infiltrates or pulmonary fibrosis [55, 56]. Based on the
accumulating information on clinical cases, the effects of
an anti-IL-6 strategy on ILD should be observed carefully.
Conclusion
In the present study, we clearly demonstrated that the role
of IL-6 signaling could differ between the inflammatory and
fibrotic stages of BLM-induced lung injury. In particular,
blockade of IL-6 at the early inflammatory stage of BLM-
induced lung injury can lead to apoptosis and functional
change of type 2 pneumocytes and accelerate lung fibrotic
formation partly by regulating TGF-β1 expression. BLM
eventually effectively induces lung fibrosis, suggesting that
the protective role of IL-6 as a compensatory mechanism
cannot intrinsically overcome BLM-induced lung fibrosis
and is masked in the final pathological outcome. Consider-
ing an anti-IL-6 strategy against lung inflammatory disease,
however, this compensatory mechanism could be a crucial
element in management of the disease.
Additional files
Additional file 1: Figure S1. Blockade of IL-6 at early inflammatory
stage of BLM-injured lung affects SMA induction in the lung. Mice were
intratracheally administered with IL-6-neutralizing antibody or isotype
control at 6, 30 and 54 h (0, 1 and 2 dpi) after instillation of BLM. Then,
the left lung lobes were dissected out at 5, 7 and 14 dpi. The left lung
lobes of untreated mice were used as negative control (N.C.). The lobe
was longitudinally cut into two pieces, each of which was used for
protein preparation and total RNA preparation, respectively. Total RNA
was used for determination of TGF-β1 mRNA (See Figure S2A). Protein
samples (5 μg) were subjected to Western blot analysis with anti-SMA
and anti-β-actin. The signal of each sample was determined by using a
densitometer and normalized to each internal control (β-actin). Signal
values were expressed as relative fold induction to the N.C. #1 (1.0).
Similar results were obtained in two independent experiments.
(PDF 1495 kb)
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Additional file 2: Figure S2. Blockade of IL-6 at early inflammatory
stage of BLM-injured lung affects TGF-β1 induction in the lung. A) Total
RNA from each sample corresponding to the experimental condition in
Figure S1 was subjected to RT-PCR for amplification of TGF-β1 and
GAPDH cDNAs. The specific primers and the settings of the thermal
cycler employed here were accordant with our previous report [Ref. 5,
Yamauchi K, et al.]. The amplified products were separated on a 1.5 %
agarose gel and visualized with ethidium bromide staining under UV
radiation. The signal of each sample was determined by using a
densitometer and normalized to each internal control (GAPDH). Signal
values were expressed as relative fold induction to the N.C. #1 (1.0).
Similar results were obtained in two independent experiments. At 7 dpi,
blockade of IL-6 positively regulated the BLM-induced TGF-β1 mRNA
expression. Then, we further elucidated this possibility. B) The whole lung
lobes from three groups of mice (PBS group, BLM+control IgG group and
BLM+anti-IL-6 group) were dissected out at 7 dpi. Total RNA (0.1 μg) from
each sample was subjected to RT-PCR for amplification of TGF-β1 and
GAPDH cDNAs, and each densitometric signal was obtained. Normalized
signal values were expressed as relative fold induction to one of the
values in PBS group. Data are shown as mean ± S.E.M. (n=6). *P < 0.05,
significantly different between values of three groups (ANOVA followed
by Tukey's test). (PDF 1290 kb)
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